BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

基本信息

批准号：
10618274
负责人：
CHARLES E. CHALFANT
金额：
--
依托单位：
VA VETERANS ADMINISTRATION HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10618274
关键词：
Address Affinity Aging American Anabolism Anoikis Appointment Area Arts Asbestos Award Basic Science Binding Binding Sites Biochemistry Biology Biomedical Research Cancer Etiology Cancer Patient Carcinogens Caring Cause of Death Cell Survival Cellular biology Cessation of life Clinical Collaborations Communication Communities Department chair Developed Countries Development Disease Eicosanoid Production Eicosanoids Elements Endowment Event Exposure to Faculty Florida Funding Glycerol Goals Grant Head Healthcare Healthcare Systems Heart Arrest Heterogeneous-Nuclear Ribonucleoprotein L Human Individual Inflammatory Inflammatory Response Inorganic Phosphate Transporter Institution Ionizing radiation Journals Laboratories Laboratory Study Link Lipids Lung Maintenance Malignant Neoplasms Malignant neoplasm of lung Manuscripts Mediating Mentors Microbiology Military Personnel Mission Molecular Molecular Biology N-terminal Natural Sciences Nature Non-Small-Cell Lung Carcinoma Oncology Outcome Patient Care Patient-Focused Outcomes Peer Review Peripheral Phospholipase Phosphorylation Site Productivity Prognosis Proteins Publications Publishing RNA RNA Recognition Motif RNA Sequences RNA Splicing Reporting Research Research Personnel Resistance Resources Role Science Scientist Sepsis Series Services Signal Transduction Smoke Societies Sphingolipids Study Section Survival Rate System Therapeutic Tobacco Dependence Training Traumatic injury United States Department of Veterans Affairs United States National Institutes of Health Universities Veterans Veterans Health Administration Veterans Hospitals Woman Work acute wound agent orange anticancer research cancer cell cancer diagnosis career cellular targeting ceramide 1-phosphate ceramide kinase chronic wound clinical predictors clinical translation college editorial former smoker high risk human disease innovation lipidomics lung cancer cell lung development malignant breast neoplasm member men military service military veteran molecular targeted therapies new therapeutic target novel novel therapeutics phenome preference programs senior faculty tobacco abuse transcriptome sequencing tumor wound healing

项目摘要

Cancer is the second leading cause of death among veterans, and the Veterans Health Administration estimates that there exist >170,000 cancer patients within in the VA system. Moreover, approximately 50,000 new cases of cancer are diagnosed each year. With the aging of the veteran population, this number is expected to increase causing a concomitant encumbering of healthcare resources. Lung cancer, which is the leading cause of death in both men and women in industrialized countries (an estimated 28% of all cancer deaths in the USA), is also the leading cause of cancer death in the veteran population. Indeed, many veterans continue to acquire tobacco addiction during their military service even though tobacco abuse is currently discouraged by the military. Hence, there exists a very large percentage of high-risk current and former smokers cared for in the VA health care system that would benefit from advances in therapeutic molecular targeting in the treatment of lung cancer. Also, lung cancer is also linked to the well-established lung carcinogens, Agent Orange, Asbestos, and Ionizing Radiation, which exposure to these agents are often are service-connected disorders. To address this issue, the research of the Chalfant Laboratory focuses on non-small cell lung cancer (NSCLC), which represents the majority of lung cancers, carries a poor prognosis with a median survival of less than 12 months, and has a cumulative five-year survival rate of approximately 15%. The research of the Chalfant Laboratory is tailored to identify new cellular targets for the development of new treatments for this deadly disease, which are thus, directly relevant to the patient care mission of the Department of Veterans Affairs. Indeed, biomedical research investigating new strategies for the development of lung cancer therapeutics has tremendous potential benefit to veterans, many of whom no longer smoke, yet remain at high risk for NSCLC. The Chalfant Laboratory focuses on two major, but diverse areas of basic science in regard to Cell Biology, Microbiology, and Molecular Biology. Specifically, the Chalfant Laboratory studies mechanisms of cell signaling associated with both bioactive lipids and RNA splicing with a focus on both basic science mechanisms as well as in many cases clinical translation. In regard to RNA splicing research, the Chalfant Laboratory has identified key RNA splicing events and signaling mechanisms mediating the tumor maintenance of NSCLC cells. The applicant is further merging these finding with novel lipid signaling events linked to cell survival. The applicant, Dr. Chalfant, has been very productive with >100 peer-reviewed publications, and he has been a distinguished member of the VA system for 17 years. His research work is supported by several NIH/VA funded projects and currently, he has one VA Merit Review award and three NIH funded projects (2-R01 and 1- U01). He has trained more than 40 trainees at very levels with a number of them currently faculty members at various institutions with funded research programs. The applicant is an unselfish mentor of young investigators allowing them to act as co-corresponding authors on numerous publications for the betterment of their careers. The applicant continues to be a leader in his scientific field as shown by appointments to several Editorial Boards and National Committees, which include: the editorial boards of the Journal of Lipid Research. Molecular Cancer Research, and the Journal of Biological Chemistry, formal membership on the Cancer and Molecular Pathobiology Study Section of the National Institutes of Health, and formal membership on the Oncology A Study Section of the Veterans’ Administration. These areas of research also led to the communication of the 2011 ASBMB Avanti Junior Investigator Award for Lipid Research to Dr. Chalfant. The applicant has also extensively collaborated with numerous investigators in funded program projects and scientific publications. In summary, the applicant’s scientific contributions are vitally important to the VA mission. He has made ground breaking discoveries in the field of NSCLC, RNA Splicing, Lipidomics, and Lipid Signaling and has also provided significant resources to the scientific community and the VA system.

癌症是退伍军人和退伍军人卫生管理局的第二大死亡原因估计在VA系统中存在> 170,000名癌症患者。此外，大约50,000 每年诊断出新的癌症病例。随着退伍军人人口的衰老，预计这个数字增加导致医疗资源的伴随。肺癌，这是领先的工业化国家男性和女性死亡原因（估计所有癌症死亡的28％美国也是退伍军人人口中癌症死亡的主要原因。确实，许多退伍军人继续即使目前拒绝烟草滥用烟草，也会在服兵役期间获得烟草成瘾军队。因此，存在着很大一部分的高风险电流和前吸烟者 VA医疗保健系统将受益于治疗的治疗分子靶向的进步肺癌。此外，肺癌还与已建立的肺癌，特工橙，石棉，与这些药物接触的电离辐射通常是连接的疾病。为了解决这个问题，Chalfant实验室的研究集中于非小细胞肺癌（NSCLC）代表大多数肺癌，其预后不良，中位生存率较少超过12个月，累积的五年生存率约为15％。 Chalfant的研究实验室量身定制，旨在确定新的蜂窝靶标，以开发这种致命的新疗法因此，疾病与退伍军人事务部的患者护理任务直接相关。实际上，研究肺癌疗法开发的新策略的生物医学研究已有对退伍军人的巨大潜在好处，其中许多人不再吸烟，但仍处于NSCLC的高风险。 Chalfant实验室重点介绍了两个基础科学领域的两个主要领域生物学，微生物学和分子生物学。具体而言，Chalfant实验室研究机制与生物活性脂质和RNA剪接相关的信号传导，重点是两种基础科学机制以及在许多情况下临床翻译。关于RNA剪接研究，Chalfant实验室具有确定了介导NSCLC细胞肿瘤维持的关键RNA剪接事件和信号传导机制。申请人将这些发现与与细胞存活有关的新型脂质信号事件进一步合并。申请人Chalfant博士在经过> 100个同行评审的出版物中非常有生产力，他有他是VA系统的杰出成员，已有17年了。他的研究工作得到了几位NIH/VA的支持资助的项目，目前，他获得了一项VA优异审查奖和三个NIH资助的项目（2-R01和1-- U01）。他已经在非常层次的情况下培训了40多位学员，目前有许多教师具有资助研究计划的各种机构。申请人是年轻调查员的无私的心理允许他们担任众多出版物的共同作者，以改善其职业生涯。申请人继续是他的科学领域的领导者，如几个编辑委员会的任命所示和国家委员会，其中包括：脂质研究杂志的编辑委员会。分子癌研究，以及生物化学杂志，癌症和分子的正式成员资格美国国立卫生研究院的病理生物学研究部分和肿瘤学的正式会员资格研究退伍军人政府的部分。这些研究领域也导致了2011年的交流 ASBMB Avanti初级研究者脂质研究奖授予Chalfant博士。申请人也广泛与众多研究人员合作，从事资助的计划项目和科学出版物。总之，申请人的科学贡献对VA任务至关重要。他做了在NSCLC，RNA剪接，脂质组学和脂质信号的领域的突破性发现，也具有为科学界和VA系统提供了大量资源。